Cytokine Gene Transduction in the Immunotherapy of Cancer

Advances in Pharmacology

Volumn 40, Issue C, 1997, Pages 259-307

  Parmiani, Giorgio ^a   Colombo, Mario P ^a   Melani, Cecilia ^a   Arienti, Flavio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

ANIMAL; BIOSYNTHESIS; EXPERIMENTAL NEOPLASM; GENE THERAPY; GENETIC TRANSDUCTION; GENETICS; HUMAN; IMMUNOTHERAPY; NEOPLASM; REVIEW;

ANIMALS; CYTOKINES; GENE THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; TRANSDUCTION, GENETIC;

EID: 0030627634     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(08)60142-8     Document Type: Article

References (207)

1. Addison C.L., Braciak T., Ralston R., Muller W.J., Gauldie J., and Graham F.L. Intratumoral injection of an adenovirus expressing interleukin 2 induced regression and immunity in a murine breast cancer model. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 8522-8526
2. Alexander J., Rayman P., Edinger M., Connelly R., Tubbs R., Bukowski R., Pontes E., and Finke J. TIL from renal-cell carcinoma: Restimulation with tumor influences proliferation and cytolytic activity. Int. J. Cancer 45 (1990) 119-124
3. Alexander M.A., Bennicelli J., and Guerry IV D. Defective antigen presentation by human melanoma cell lines cultured from advanced, but not biologically early, disease. J. Immunol. 142 (1989) 4070-4078
4. Allione A., Consalvo M., Nanni P., Lollini P.L., Cavallo F., Giovarelli M., Forni M., Gulino A., Colombo M.P., Dellabona P., Hock H., Blankenstein T., Rosenthal F.M., Gansbacher B., Bosco M.C., Musso T., Gusella L., and Forni G. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor α, granulocyte-macrophage colony-stimulating factor, and γ-interferon gene or admixed with conventional adjuvants. Cancer Res. 54 (1994) 6022-6026
5. Angelini G., Fossati G., Radice P., Longo A., Piccioli P., Pierotti M.A., Ferrara G.B., and Parmiani G. Loss of polymorphic restriction fragments of class I and class II MHC genes in a malignant melanoma. J. Immunogenet. 13 (1986) 241-246
6. Anichini A., Maccalli C., Mortarini R., Salvi S., Mazzocchi A., Squarcina P., Herlyn M., and Parmiani G. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2 restricted cytotoxic T-cell clones from melanoma patients. J. Exp. Med. 177 (1993) 989-998
7. Anichini A., Mortarini R., Alberti S., Mantovani A., and Parmiani G. T-cell receptor engagement and tumor ICAM-1 up-regulation are required to by-pass low susceptibility of melanoma cells to autologous CTL-mediated lysis. Int. J. Cancer 53 (1993) 994-1001
8. Arienti F., Belli F., Gambacorti-Passerini C., Furlan L., Mascheroni L., Prada A., Rizzi M., Marchesi E., Vaglini M., Parmiani G., and Cascinelli N. Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL2. Cancer Immunol. Immunother. 36 (1993) 315-322
9. Arienti F., Sulé-Suso J., Melani C., Maccalli C., Belli F., Illeni M.T., Anichini A., Cascinelli N., Colombo M.P., and Parmiani G. Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes. Hum. Gene Ther. 5 (1994) 1139-1150
10. Arienti F., Sulé-Suso J., Belli F., Mascheroni L., Rivoltini L., Melani C., Maio M., Caseinelli N., Colombo M.P., and Parmiani G. Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. Hum. Gene Ther. 7 (1996) 1955-1963
11. Asher A.L., Mulé J.J., Kasid A., Restifo N.P., Salo J.C., Reichert C.M., Jaffe G., Fendly B., Kriegel M., and Rosenberg S.A. Murine tumor cells transduced with Th gene for tumor necrosis factor-α. J. Immunol. 146 (1991) 3227-3234
12. Bakker A.B.H., Schreurs M.W.J., de Boer A.J., Kawakami Y., Rosenberg S.A., Adema G., and Figdor C. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 179 (1994) 1005-1009
13. Bannerji R., Arroyo C.D., Cordon-Cardo C., and Gilboa E. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J. Immunol. 152 (1994) 2324-2333
14. Bartlett J.S., Quartrocchi K.B., and Samulski R.J. The development of adeno-associated virus as a vector for cancer gene therapy. In: Sobol R.E., and Scanlon K.J. (Eds). The Internet Book of Gene Therapy: Cancer Therapeutics (1995), Appleton & Lange, Stamford, Connecticut. 27-39
15. Belldegrun A., Muul L.M., and Rosenberg S.A. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: Isolation, characterization, and antitumor activity. Cancer Res. 48 (1988) 206-214
16. Belldegrun A., Tso C.-L., Sakata T., Duckett T., Brunda M.J., Barsky S.H., Chai J., Kaboo R., Lavey R.S., McBride W.H., and de Kernion J.B. Human renal carcinoma line transfected with interleukin-2 and/or interferon α gene(s): Implications for liver cancer vaccines. J. Natl. Cancer Inst. 85 (1993) 207-216
17. Berd D., Sato T., Lattime E.D., Maguire Jr. H.C., and Mastrangelo M.J. Immunization with hapten-modified tumor cells: A strategy for the treatment of human melanoma. Proc. Am. Assoc. Cancer Res. 35 (1994) 667-668
18. Bett A.J., Haddara W., Prevec L., and Graham F.L. An efficient and flexible system for construction of adenovirus vectors with insertion or deletions in early regions 1 and 3. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 8802-8806
19. Blaese R.M., Ishii-Morita H., Mullen C., Ramsey J., Ram Z., Oldfield E.O., and Culver K. In situ delivery of suicide genes for cancer treatment. Eur. J. Cancer 30A (1994) 1190-1193
20. Blankenstein T., Qin Z., Uberla K., Muller W., Rosen H., Volk H.-D., and Diamantstein T. Tumor suppression after tumor cell-targeted tumor necrosis factor α gene transfer. J. Exp. Med. 173 (1991) 1047-1052
21. Boon T., Cerottini J.-C., Van den Eynde B., van der Bruggen P., and Van Pel A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12 (1994) 337-365
22. Bosco M., Giovarelli M., Forni M., Modesti A., Scarpa S., Masuelli L., and Forni G. Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory. J. Immunol. 145 (1990) 3136-3143
23. Boviatsis E.F., Park J.S., Sena-Esteves M., Kramm C.M., Chase M., Efird J.T., Wei M.X., Breakefield X.O., and Chiocca A.E. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res. 54 (1994) 5745-5751
24. Brändle D., Brasseur F., Weynants P., Boon T., and Van den Eynde B. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J. Exp. Med. 183 (1996) 2501-2508
25. Brenner M.K., Furman W.L., Santana V.M., Bowman L., and Meyer W. Phase I study of cytokine-gene modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma. Hum. Gene Ther. 3 (1992) 665-676
26. Brody S.L., Jaffe A., Han S.K., Werstor P., and Crystal R.G. Direct in vivo gene transfer and expression in malignant cells using adenovirus vectors. Hum. Gene Ther. 15 (1994) 437-447
27. Bronte V., Tsung K., Rao J.B., Chen P.W., Wang M., Rosenberg S.A., and Restifo N.P. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastasis. J. Immunol. 154 (1995) 5282-5292
28. Brunda M.J., Luistro L., Warrier R.R., Wright R.B., Hubbard B.R., Murphy M., Wolf S.F., and Gately M.K. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J. Exp. Med. 178 (1993) 1223-1230
29. Bubenik J., Voitenok N.N., and Kieler J. Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumors in nu/nu mice. Immunol. Lett. 19 (1988) 279-282
30. Carbone F.R., Moore M.W., Sheil J.M., and Bevan M.J. Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides. J. Exp. Med. 167 (1988) 1767-1779
31. Cascinelli N., Foa R., and Parmiani G. Active immunization of metastatic melanoma patients with interleukin-4 transduced, allogeneic melanoma cells: A phase I-II study. Hum. Gene Ther. 5 (1994) 1059-1064
32. Cavallo F., Giovarelli M., Gulino A., Vacca A., Stoppacciaro A., Modesti A., and Forni G. Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene transfection. J. Immunol. 149 (1992) 3627-3635
33. Cavallo F., Di Pierro F., Giovarelli M., Gulino A., Vacca A., Stoppacciaro A., Forni M., Modesti A., and Forni G. Protective and curative potential of vaccination with interleukin-2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma. Cancer Res. 53 (1993) 5067-5070
34. Celis E., Tsai V., Crimi C., DeMars R., Wentworth P.A., Chesnut R.W., Grey H.M., Sette A., and Serra H.M. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 2105-2109
35. Cepko C.L., Roberts B.E., and Mulligan R.C. Construction and application of a highly transmissible murine retrovirus shuttle vector. Cell (Cambridge, Mass.) 37 (1984) 1053-1062
36. Cheever M.A., Disis M.L., Bernhard H., Gralow J.R., Hand S.L., Huseby E.S., Qin H.L., Takahashi M., and Chen W. Immunity to oncogenic proteins. Immunol. Rev. 145 (1995) 33-59
37. Chen S.H., Chen H.X., Wang Y., Kosai K., Finegold M.J., Rich S., and Woo S.L.C. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 2577-2581
38. Cignetti A., Guarini A., Carbone A., Forni M., Cronin K., Forni G., Gansbacher B., and Foà R. Transduction of the IL2 gene into human acute leukemia cells: Induction of tumor rejection without modifying cell proliferation and IL2 receptor expression. J. Natl. Cancer Inst. 86 (1994) 785-791
39. Colombo M.P., and Forni G. Cytokine gene transfer in tumor inhibition and tumor therapy: Where are we now?. Immunol. Today 15 (1994) 47-51
40. Colombo M.P., Ferrari G., Stoppacciaro A., Parenza M., Rodolfo M., Mavilio F., and Parmiani G. Granulocyte colony-stimulating factor gene suppresses tumorigenicity of a murine adenocarcinoma in vivo. J. Exp. Med. 173 (1991) 1093-1102
41. Colombo M.P., Maccalli C., Mattei C., Melani C., Radrizzani M., and Parmiani G. Expression of cytokines genes, including IL-6, in human malignant melanoma cell lines. Melanoma Res. 2 (1992) 181-189
42. Colombo M.P., Modesti A., Parmiani G., and Forni G. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte crosstalk. Cancer Res. 52 (1992) 4853-4857
43. Connor J., Bannerji R., Saito S., Heston W., Fair W., and Gilboa E. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J. Exp. Med. 177 (1993) 1127-1134
44. Cordier L., Duffour M.T., Sabourin J.C., Lee M.G., Cabannes J., Ragot T., Perricaudet M., and Haddada H. Complete recovery of mice from a pre-established tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene. Gene Ther. 2 (1995) 16-21
45. Culver K.W., Ram Z., Wallbridge S., Ishii H., Oldfield E.M., and Blaese M. In vivo gene transfer with retroviral-vector producer cells for treatment of experimental brain tumors. Science 256 (1992) 1550-1552
46. Danos O., and Mulligan R.C. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host range. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 6460-6464
47. Dermime S., Molldrem J., Parker K.C., Jiang Y.Z., Mavroudis D., Hensel N., Couriel D., Mahonev M., Coligan J.E., and Barrett A.J. Human CD8+ T lymphocytes recognize the fusion region of BCR/ABL hybrid protein present in chronic myelogenous leukemia. Blood 86s1 (1995) 158a
48. Dermime S., Bertazzoli C., Marchesi E., Ravagnani F., Blaser K., Corneo G.M., Parmiani G., and Gambacorti-Passerini C. Lack of T-cell mediated recognition of the fusion region of the PML/RARα hybrid protein by lymphocytes of acute promyelocytic leukemia patients. Clin. Cancer Res. 2 (1996) 593-600
49. Doerfler W. The abortive infection and malignant transformation by adenoviruses: Integration of viral DNA and control of viral gene expression by specific patterns of DNA methylation. Adv. Virus Res. 39 (1991) 89-128
50. Dorsch M., Hock H., Kuzendorf U., Diamantstein T., and Blankenstein T. Macrophage colony-stimulating factor gene transfer into tumor cells induces macrophage infiltration but not tumor suppression. Eur. J. Immunol. 23 (1993) 186-190
51. Douvdevani A., Huleihel M., Zoller M., Segal S., and Apte R.N. Reduced tumorigenicity of fibrosarcomas which constitutively generate IL-1α either spontaneously or following IL-1α gene transfer. Int. J. Cancer 51 (1992) 822-830
52. Dranoff G., Jaffee E.M., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D., and Mulligan R.C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 3539-3543
53. Dzierzak E.A., Papayannopoulou T., and Mulligan R.C. Lineage-specific expression of a human B-globin gene in murine bone marrow transplant reconstituted with retrovirus-transduced stem cells. Nature (London) 331 (1988) 35-41
54. Estin C.D., Stevenson U.S., Plowman G.D., Hu S.L., Sriddar P., Hellström I., Brown J.P., and Hellström K.E. Recombinant vaccinia virus vaccine against human melanoma antigen p97 for use in immunotherapy. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 1052-1056
55. Fakhrai H., Shawler D.L., Gjerset R., Naviaux R.K., Koziol J., Royston I., and Sobol R.E. Cytokine gene therapy with interleukin-2-transduced fibroblasts: Effects of IL-2 dose on anti-tumor immunity. Hum. Gene Ther. 6 (1995) 591-601
56. Fearon E.R., Pardoll D.M., Itaya T., Golumbeck P., Levitsky H.I., Simons J.W., Karasuyama H., Vogelstein B., and Frost P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell (Cambridge, Mass.) 60 (1990) 397-403
57. Ferrantini M., Proietti E., Santodonato L., Gabriele L., Peretti M., Plavec I., Meyer F., Kaido T., Gresser I., and Belardelli F. α1-interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: Antitumor therapy by means of interferon-producing cells. Cancer Res. 53 (1993) 1107-1112
58. Ferrone S., and Marincola F. Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance. Immunol. Today 16 (1995) 487-494
59. Fink D.J., Sternberg L.R., Weber P.C., Mata M., Goins W.F., and Glorioso J.C. In vivo expression of β-galactosidase in hippocampal neurons by HSV-mediated gene transfer. Hum. Gene Ther. 3 (1992) 11-19
60. Finn O.J. Tumor rejection antigens recognized by T lymphocytes. Curr. Opin. Immunol. 5 (1993) 701-708
61. Fitch F.W., McKisic M.D., Laucki D.W., and Gajewski T.F. Differential regulation of murine T lymphocyte subsets. Annu. Rev. Immunol. 11 (1993) 29-48
62. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat. Med. 1 (1995) 27-31
63. Forni G., Giovarelli M., Santoni A., Modesti A., and Forni M. Tumour inhibition by interleukin-2 at the tumour/host interface. Biochim. Biophys. Acta 865 (1986) 307-327
64. Forni G., Musso T., Jemma C., Boraschi D., Tagliabue A., and Giovarelli M. Lymphokine-activated tumor inhibition (LATI) in mice: Ability of a nonapeptide of the human interleukin-1 to recruit antitumor reactivity in recipient mice. J. Immunol. 142 (1989) 712-718
65. Forni G., Cavallo F., Consalvo M., Allione A., Dellabona P., Casorati G., and Giovarelli M. Molecular approaches to cancer immunotherapy. Cytokine Mol. Ther. 1 (1995) 225-248
66. Gajewski T., Renauld J.-C., Van Pel A., and Boon T. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro. J. Immunol. 154 (1995) 5637-5648
67. Gambacorti-Passerini C., Grignani F., Arienti F., Pandolfi P.P., Pelicci P.G., and Parmiani G. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RARα present in acute promyelocytic leukemia cells. Blood 81 (1993) 1369-1375
68. Gansbacher B., Bannerji R., Daniels B., Zier K., Cronin K., and Gilboa E. Retroviral vector-mediated γ interferon gene transfer to tumor cells generates potent and long lasting antitumor immunity. Cancer Res. 50 (1990) 7820-7825
69. Gansbacher B., Zier K., Daniels B., Cronin K., Bannerji R., and Gilboa E. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172 (1990) 1217-1224
70. Gansbacher B., Zier K., Cronin K., Hantzopoulos P.A., Bouchard B., Houghton A., Gilboa E., and Golde D. Retroviral transfer induced constitutive expression of interleukin-2 or interferon in irradiated human melanoma cells. Blood 80 (1992) 2817-2825
71. Gansbacher B., Houghton A., and Livingston P. A pilot study of immunization with HLA-A2 matched allogeneic melanoma cells that secrete interleukin-2 in patients with metastatic melanoma. Hum. Gene Ther. 3 (1992) 677-690
72. Garrido F., Cabrera T., Concha A., Glew S., Ruiz-Cabello F., and Stern P. Natural history of HLA expression during tumour development. Immunol. Today 14 (1993) 491-499
73. Gastl G., Finstad C.L., Guarini A., Bosl G., Gilboa E., Bander N.H., and Gansbacher B. Retroviral vector-mediated gene transfer into human renal cancer cells. Cancer Res. 52 (1992) 6229-6236
74. Gaugler B., Brouwenstijn N., Ventomme V., Szikora J.-P., Van der Speck C.W., Patard J.-J., Boon T., Schrier P., and Van den Eynde B.J. A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. Immunogenetics 44 (1996) 323-330
75. Geller A.I., Keyomarsi K., Bryan J., and Pardee A.B. An efficient deletion mutant packaging system for defective herpes simplex viral vectors: Potential application to human gene therapy and neuronal physiology. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 8950-8954
76. Germain R.N. MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation. Cell (Cambridge, Mass.) 76 (1994) 287-299
77. Giovarelli M., Cofano F., Vecchi A., Forni M., Landolfo S., and Form G. Interferon-activated tumor inhibition in vivo. Int. J. Cancer 37 (1986) 141-147
78. Golumbek P.T., Lazenby A.L., Levitsky H., Jaffee L.M., Karasuyama H., Baker M., and Pardoll D.M. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-6. Science 254 (1991) 713-716
79. Golumbek P.T., Azahari R., Jaffee E.M., Levitsky H., Lazenby A., Leong K., and Pardoll D.M. Controlled release, biodegradable cytokine depots: A new approach in cancer vaccine design. Cancer Res. 53 (1993) 5841-5844
80. Grabbe S., Beissert S., Schwarz T., and Granstein R.D. Dendritic cells as initiators of tumor immune response: A possible strategy for tumor immunotherapy?. Immunol. Today 16 (1995) 117-121
81. Greenberg P.D. Adoptive T-cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49 (1991) 281-355
82. Grez M., Akgun E., Hilberg F., and Ostertag W. Embryonic stem cell virus, a recombinant murine retrovirus with expression in embryonic stem cells. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 9202-9206
83. Han X., Kasahara N., and Kan Y.W. Ligand directed retroviral targeting of human breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 9747-9751
84. Hantzopoulos P.A., Sullenger B.A., Ungers G., and Gilboa E. Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 3519-3523
85. Hawley R.G., Fong A.Z.C., Burns B.F., and Hawley T.S. Transplantable myeloproliferative disease induced in mice by an interleukin 6 retrovirus. J. Exp. Med. 176 (1992) 1149-1163
86. Herlyn M., Kath R., Williams N., Valyi-Nagy I., and Rodeck U. Growth regulatory factors for normal, premalignant, and malignant human cells in vitro. Adv. Cancer Res. 54 (1990) 213-254
87. Hersey P. Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma. World J. Surg. 16 (1992) 251-260
88. Hock H., Dorsch M., Diamantstein T., and Blankenstein T. Interleukin-7 induces CD4+ T cell-dependent tumor rejection. J. Exp. Med. 174 (1991) 1291-1298
89. Hock H., Dorsch M., Kunzendorf U., Qin Z., and Diamantstein T. Mechanism of rejection induced by tumor cells targeted gene transfer of interleukin-2, interleukin-4, interleukin-7, tumor necrosis factor or interferon-gamma. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 2774-2778
90. Hock H., Dorsch M., Kunzendorf U., Überla K., Qin Z., Diamantstein T., and Blankenstein T. Vaccinations with tumor cells genetically engineered to produce different cytokines: Effectively not superior to a classical adjuvant. Cancer Res. 53 (1993) 714-716
91. Houbiers J.G.A., Nijman N.W., Van der Burg S.H., Drijfhout J.W., Kenemans P., Van de Velde C.J.N., Braud A., Momburg F., Kasy M.W., and Melief C.J.M. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild type p53. Eur. J. Immunol. 23 (1993) 2072-2077
92. Huang A.Y.C., Golumbek P., Ahmadzadeh M., Jaffee E., Pardoll D.M., and Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264 (1994) 961-965
93. Hurford Jr. R.K., Dranoff G., Mulligan R.C., and Tepper R.I. Gene therapy of metastatic cancer by in vivo retroviral gene targeting. Nat. Genet. 10 (1995) 430-435
94. Jaffee E.M., Dranoff G., Cohen L.K., Hauda K.M., Clift S., Marshall F.F., Mulligan R.C., and Pardoll D.M. High efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res. 53 (1993) 2221-2226
95. Jaffee E.M., Lazenby A., Meurer J., Marshall F., Hauda K.M., Counts C., Hurwitz H., Simons J.W., Levitsky H.I., and Pardoll D.M. Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials. J. Immunother. 18 (1995) 1-9
96. Jolly D. Viral vector system for gene therapy. In: Sobol R.E., and Scanlon K.J. (Eds). The Internet Book of Gene Therapy: Cancer Therapeutics (1995), Appleton & Lange, Stamford, Connecticut. 3-16
97. Kaido T., Bandu M.-T., Maury C., Ferrantini M., Belardelli F., and Gresser I. IFN-α1 gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice. Int. J. Cancer 60 (1995) 221-229
98. Kaneko C., Hallenbeck P., Nakabayashi H., McGarrity G., Tamaoki T., Anderson F.W., and Chiang Y.L. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res. 55 (1995) 5283-5287
99. Kantor J., Irvine K., Abrams S., Kaufman H., DiPietro J., and Schlom J. Antitumor activity and immune response induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J. Natl. Cancer Inst. 84 (1992) 1084-1091
100. Kawakami Y., and Rosenberg S.A. T-cell recognition of self peptides as tumor rejection antigens. Immunol. Res. 15 (1996) 179-190
101. Kehrl J.H., Wakefield L.M., Roberts A.B., Jakowlew S.B., Alvarez-Mon M., Derynck R., Sporn M.B., and Fauci A.S. Production of transducing growth factor β by human lymphocytes and its potential role in regulation of T-cell growth. J. Exp. Med. 163 (1986) 1037-1050
102. Kerbel R. Expression of multi-cytokine resistance and multi-growth factor independence in advanced stage metastatic cancers. Am. J. Pathol. 141 (1992) 510-524
103. Kim T.S., and Cohen E.P. Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine melanoma cells prolong the survival of mice with melanoma. Cancer Res. 54 (1994) 2531-2535
104. Kim T.S., Russel S.J., Collins M.K.L., and Cohen E.P. Immunization with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens prolongs the survival of mice with melanoma. Int. J. Cancer 55 (1993) 865-872
105. Kim T.-Y., von Eschenbach A.C., Filaccio M.D., Hayakawa K., Parkinson D.R., Balch C.M., and Itoh K. Clonal analysis of lymphocytes from tumor, peripheral blood, and nontumorous kidney in primary renal cell carcinoma. Cancer Res. 50 (1990) 5263-5268
106. Krüger-Krasagakes S., Li W., Richter G., Diamantstein T., and Blankenstein T. Eosinophils infiltrating interleukin-5 gene-transfected tumors do not suppress tumor growth. Eur. J. Immunol. 23 (1993) 992-995
107. Lau C., Soriano H.E., Ledley F.D., Finegold M.J., Wolfe J.H., Birkenmeier E.H., and Henning S.J. Retroviral gene transfer into the intestinal epithelium. Hum. Gene Ther. 6 (1995) 1145-1151
108. Ledley F.D. Nonviral gene therapy: The promise of genes as pharmaceutical products. Hum. Gene Ther. 6 (1995) 1129-1144
109. Lehman F., Marchand M., Hainaut P., Pouillart P., Sastre X., Ikeda H., Boon T., and Coulie P.G. Differences in the antigens recognized by cytolytic T-cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur. J. Immunol. 25 (1995) 340-347
110. Lollini P.-L., Bosco M.C., Cavallo F., De Giovanni C., Giovarelli M., Landuzzi L., Musiani P., Modesti A., Nicoletti G., Palmieri G., Santoni A., Young H.A., Forni G., and Nanni P. Inhibition of tumor growth and enhancement of metastasis after transfection of the γ-interferon gene. Int. J. Cancer 55 (1993) 320-329
111. Lotze M.T., and Rubin J.T. Gene therapy of cancer: A pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response. Hum. Gene Ther. 5 (1994) 41-55
112. M.T. Lotze, J.T. Rubin, (1995). Protocol #9209-033 (Gene therapy of cancer: A pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response). RAC Rep. June, 16.
113. Maass G., Schmidt W., Berger M., Schilcher F., Koszik F., Schneeberger A., Stingl G., Birnstiel M.L., and Schweighoffer T. Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: Three consecutive stages may be required for successful tumor vaccination. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 5540-5544
114. Mantovani A., Bottazzi B., Colotta F., Sozzani S., and Ruco L. The origin and function of tumor-associated macrophages. Immunol. Today 13 (1992) 265-270
115. Markowitz D., Goff S., and Bank A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167 (1988) 400-406
116. Martinotti A., Stoppacciaro A., Vagliani M., Melani C., Spreafico F., Wysocka M., Parmiani G., Trinchieri G., and Colombo M.P. CD4 T-cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur. J. Immunol. 25 (1995) 137-146
117. Martuza R.L., Malik A., Markert J.M., Ruffner K.J., and Coen D.M. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252 (1991) 854-856
118. Mattei S., Colombo M.P., Melani C., Silvani A., Parmiani G., and Herlyn M. Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int. J. Cancer 56 (1994) 853-857
119. Mäurer M.J., Gollin S., Martin D., Swaney W., Bryant J., Castelli C., Robbins P., Parmiani G., Storkus W., and Lotze M.T. Escape from immune recognition: Lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J. Clin. Invest. 98 (1996) 1633-1641
120. Mazzocchi A., Rodolfo M., Parmiani G., and Anichini A. An autologous T-cell clone overcomes intra-melanoma heterogeneity for susceptibility to cell-mediated lysis by using multiple lytic mechanisms: In vitro and in vivo analysis. Melanoma Res. 1 (1991) 169-176
121. Mazzocchi A., Belli F., Mascheroni L., Vegetti C., Parmiani G., and Anichini A. Frequency of cytotoxic T lymphocyte precursors (CTLp) interacting with autologous tumor via the T-cell receptor: Limiting dilution analysis of specific CTLp in peripheral blood and tumor-invaded lymph nodes of melanoma patients. Int. J. Cancer 58 (1994) 330-339
122. McAdam A.J., Pulaski B.A., Storozynsky E., Yeh K.-Y., Sickel J.Z., Frelinger J.G., and Lord E.M. Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocyte-monocyte colony stimulating factor, and interferon-γ) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumor. Cell. Immunol. 165 (1995) 183-192
123. McBride W.H., Thacker J.D., Comora S., Economou J.S., Kelley D., Hogge D., Dubinett S.M., and Dougherty G.J. Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity. Cancer Res. 52 (1992) 3931-3937
124. McCabe B.J., Irvine K.R., Nishimura M.I., Yang J.C., Spiess P.J., Shulman E.P., Rosenberg S.A., and Restifo N.P. Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte response. Cancer Res. 55 (1995) 1741-1747
125. Meko J.B., Yim J.H., Tsung K., and Norton J.A. High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine IL-12. Cancer Res. 55 (1995) 4765-4770
126. Melani C., Pupa S.M., Stoppacciaro A., Ménard S., Colnaghi M.I., Parmiani G., and Colombo M.P. An in vivo model to compare human leukocyte infiltration in carcinoma xenografts producing different chemokines. Int. J. Cancer 62 (1995) 572-578
127. Melani C., Sulé-Suso J., Arienti F., Maccalli C., Passerini F., Colombo M.P., and Parmiani G. A human melanoma cell line transduced with an interleukin-4 gene by a retroviral vector releases biologically active IL-4 and maintains the original tumor antigenic phenotype. Hum. Gene Ther. 6 (1995) 1427-1436
128. Miller A.D. Retrovirus packaging cells. Hum. Gene Ther. 1 (1990) 5-14
129. Miller A.D., Miller D.G., Garcia J.V., and Lynch C.M. Use of retroviral vectors for gene transfer and expression. In: Wu R. (Ed). Methods in Enzymology 217 (1993), Academic Press, San Diego, California. 581-599
130. Miller A.R., McBride W.H., Dubinett S.M., Dougherty G.J., Thacker J.D., Shau H., Kohn D.B., Moen R.C., Walker M.J., Chiu R., Schuk B.L., Rosenblatt J.A., Huang M., Dhanani S., Rhoades K., and Economou J.S. Transduction of human melanoma cell lines with the human interleukin-7 gene using retroviral-mediated gene transfer: Comparison of immunologic properties with interleukin-2. Blood 82 (1993) 3686-3694
131. Mitchell M.S. Active specific immunotherapy of melanoma. Br. Med. Bull. 51 (1995) 631-646
132. Moolten F.L., and Cupples A.L. A model for predicting the risk of cancer consequent to retroviral gene therapy. Hum. Gene Ther. 3 (1992) 479-486
133. Morgan R.A., Couture L., Eloroy-Stein O., Ragheb J., Moss B., and Anderson W.F. Retroviral vectors containing putative internal ribosome entry sites: Development of a polycistronic gene transfer system and applications to human gene therapy. Nucleic Acids Res. 20 (1992) 1293-1299
134. Morton D.L., Foshag L.J., Hoon D.S.B., Nizze A., Wanek L.A., Chang C., Davtyan D.G., Gupta R.K., Elashoff R., and Irie R.F. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg. 216 (1992) 463-482
135. Moss B., and Flexner C. Vaccinia virus expression vectors. Annu. Rev. Immunol. 5 (1987) 305-324
136. Mukherji B., Chakraborty N.G., Yamasaki S., Okino T., Yamase H., Sporn J.R., Kurtzman S.K., Ergin M.T., Ozols J., Meehan J., and Mauri F. Induction of antigen-specific cytolytic T-cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 8078-8082
137. Mullen C.A., Coale M., Levy A.T., Stetler-Stevenson W.G., Liotta L.A., Brandt S., and Blaese R.M. Fibrosarcoma cells transduced with the IL-6 gene exhibit reduced tumorigenicity, increased immunogenicity and decreased metastatic potential. Cancer Res. 52 (1992) 6020-6024
138. Mulligan R.C. The basic science of gene therapy. Science 260 (1993) 926-932
139. Muro-Cacho C.A., Sumulsky R.L., and Kaplan D. Gene transfer in human lymphocytes using a vector based on adeno-associated virus. J. Immunother. 11 (1992) 231-237
140. Nabel E.G., Yang Z., Muller D., Chang A., Gao X., Huang L., Cho K.J., and Nabel G.J. Safety and toxicity of catheter gene delivery to the pulmonary vasculature in a patient with metastatic melanoma. Hum. Gene Ther. 5 (1994) 1089-1094
141. Nabel G.J., Nabel E.G., Yang Z.-Y., Fox B.A., Plautz G.E., Gao X., Huang L., Shu S., Gordon D., and Chang A.E. Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 11307-11311
142. Ogasawara M., and Rosenberg S.A. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with γ-interferon genes. Cancer Res. 53 (1993) 3561-3568
143. Osanto S., Brouwenstyn N., Figdor C.G., Melief C.J.M., and Schrier P. Immunization with interleukin-2 transfected melanoma cells: A phase I-II study in patients with metastatic melanoma. Hum. Gene Ther. 4 (1993) 323-330
144. Overell R.W., Weisser K.E., and Cosman D. Stably transmitted triple promoter retroviral vectors and their use in transformation of primary mammalian cells. Mol. Cell. Biol. 8 (1988) 1803-1808
145. Paglia P., Chiodoni C., Rodolfo M., and Colombo M.P. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183 (1996) 317-322
146. Pardoll D.M. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13 (1995) 399-415
147. Pardoll D.M., and Beckerleg A.M. Exposing the immunology of naked DNA vaccines. Immunity 3 (1995) 165-169
148. Parmiani G. An explanation of the variable clinical response to interleukin 2 and LAK cells. Immunol. Today 11 (1990) 113-115
149. Parmiani G., and Colombo M.P. Somatic gene therapy of human melanoma: Preclinical studies and early clinical trials. Melanoma Res. 5 (1995) 295-301
150. Patel P.M., Flemming C.L., Fisher C., Porter C.D., Thomas J.M., Gore M.E., and Collins M.K.L. Generation of interleukin-2 secreting melanoma cell populations from resected metastatic tumors. Hum. Gene Ther. 5 (1994) 577-584
151. Paul W.E., and Seder R.A. Lymphocyte response and cytokines. Cell (Cambridge, Mass.) 76 (1994) 241-251
152. Pericle F., Giovarelli M., Colombo M.P., Ferrari G., Musiani P., Modesti A., Cavallo F., Di Piero F., Novelli F., and Forni G. An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J. Immunol. 153 (1994) 5659-5673
153. Philip R., Brunette E., Kilinski L., Murugesh D., McNally M.A., Ucar K., Rosenblatt J., Okarma T.B., and Lebkowski J.S. Efficient and sustained gene expression in primary T. lymphocytes and primary and cultured tumor cells mediated by adeno-associated virus plasmid DNA complexed to cationic liposomes. Mol. Cell. Biol. 14 (1994) 2411-2418
154. Porgador A., Tzehoval E., Katz A., Vadai E., Revel M., Feldman M., and Eisenbach L. Interleukin-6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res. 52 (1992) 3679-3686
155. Porgador A., Bannerji R., Watanabe Y., Feldman M., Gilboa E., and Eisenbach L. Antimetastatic vaccination of tumor-bearing mice with two types of IFN-γ gene-inserted tumor cells. J. Immunol. 150 (1993) 1458-1470
156. Porgador A., Gansbacher B., Bannerji R., Tzehoval E., Gilboa E., Feldman M., and Eisenbach L. Anti-metastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells. Int. J. Cancer 53 (1993) 471-477
157. Qin Z., Krüger-Krasagakes S., Kunzendorf U., Hock H., Diamantstein T., and Blankenstein T. Expression of tumor necrosis factor by different tumor cell lines results either in tumor suppression or augmented metastasis. J. Exp. Med. 178 (1993) 355-360
158. Radrizzani M., Benedetti B., Castelli C., Longo A., Ferrara G.B., Herlyn M., Parmiani G., and Fossati G. Human allogeneic melanoma-reactive T-helper lymphocyte clones: Functional analysis of lymphocyte-melanoma interactions. Int. J. Cancer 49 (1991) 1-8
159. Raz E., Carson D.A., Parker S.E., Parr T.B., Abal A.M., Aichinger G., Gromkowski S.H., Sing M., Lew D., Yankaukas M.A., Baird A.M., and Rhodes G.H. Intradermal gene immunization: The possible role of DNA uptake in the induction of cellular immunity to viruses. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 9519-9523
160. Richter G., Krüger-Krasagakes S., Hein G., Huls C., Schmitt E., Diamantstein T., and Blankenstein T. Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration. Cancer Res. 53 (1993) 4134-4137
161. Rivoltini L., Kawakami Y., Sakaguchi K., Southwood S., Sette A., Robbins P.F., Marincola F.M., Salgaller M.L., Yannelli J.R., Appella E., and Rosenberg S.A. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol. 154 (1995) 2257-2265
162. Robey E., and Allison J.P. T-cell activation: Integration of signals from the antigen receptor and costimulatory molecules. Immunol. Today 16 (1995) 306-310
163. Roe T.Y., Reynolds T.C., Yu G., and Brown P.O. Integration of murine leukemia virus DNA depends on mitosis. EMBO J. 12 (1993) 2099-2108
164. Rosenberg S.A. Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for tumor necrosis factor. Hum. Gene Ther. 3 (1992) 57-73
165. Rosenberg S.A., Lotze M.T., Yang J.C., Aebersold P.M., Linehan W.M., Seipp C., and White D.E. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. 210 (1989) 474-485
166. Rosenberg S.A., Aebersold P.M., Cornetta K., Kasid A., Morgan R.A., Moen R., Karson E.M., Lotze M.T., Yang J.C., Topalian S.L., Merino M.J., Culver K., Miller A.D.E., Blaese R.M., and Anderson W.F. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 323 (1990) 570-578
167. Rosenberg S.A., Yannelli J.R., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., Parkinson D.R., Seipp C.A., Einhorn J.H., and White D.E. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 6 (1994) 1159-1166
168. Russell S.J., Eccles S.A., Flemming C.L., Johnson C.A., and Collins M.K.L. Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL-2 cDNA. Int. J. Cancer 47 (1991) 24-251
169. Russell S.J., Hawkins R.E., and Winter G. Retroviral vectors displaying functional antibody fragments. Nucleic Acids Rres. 21 (1993) 1081-1085
170. Salgaller M.L., Weber J.S., Koening S., Yannelli J.R., and Rosenberg S.A. Generation of specific anti-melanoma activity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptides. Cancer Immunol. Immunother. 39 (1994) 105-116
171. Salgaller M.L., Afshar A., Marincola F.M., Rivoltini L., Kawakami Y., and Rosenberg S.A. Recognition of multiple epitopes in the human antigen gp 100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res. 55 (1995) 4972-4979
172. Salmons B., and Gunzburg W.H. Targeting of retroviral vectors for gene therapy. Hum. Gene Ther. 4 (1993) 129-141
173. Salter R.D., and Cresswell P. Impaired assembly and transport of HLA-A and -B antigens in a mutant T X B cell hybrid. EMBO J. 5 (1986) 943-949
174. Salvadori S., Gansbacher B., Wernick I., Tirelli S., and Zier K. B7-1 amplifies the response to interleukin-2-secreting tumor vaccines in vivo, but fails to induce a response by naive cells in vitro. Hum. Gene Ther. 6 (1995) 1299-1306
175. Schadendorf D., Moller A., Algermissen B., Worm M., Sticherling M., and Czarnetzki B.M. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J. Immunol. 151 (1994) 2667-2675
176. Schendel D.J., Gansbacher B., Oberneder R., Kriegmair M., Hofstetter A., Reithmuller G., and Segurado O.G. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. J. Immunol. 151 (1993) 4209-4220
177. Schmidt W., Schweighoffer T., Herbst E., Maass G., Berger M., Schilcher F., Schaffner G., and Bristiel M.L. Cancer vaccines: The interleukin 2 dosage effect. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 4711-4714
178. Singh R.K., Gutman M., Radinsky R., Buacana C.D., and Fidler I.J. Expression of interleukin-8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res. 54 (1994) 3242-3247
179. Somia N.V., Zoppè M., and Verma I. Generation of targeted retroviral vectors by using single-chain variable fragment: An approach to in vivo gene delivery. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 7570-7574
180. Spagnoli G.C., Schaefer C., Willimann T.E., Kocher T., Amoroso A., Juretic A., Zuber M., Luscher U., Harder F., and Heberer M. Peptide-specific, CTL in tumor-infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and tyrosinase genes: A study in an unselected group of HLA-A2.1-positive patients. Int. J. Cancer (Pred. Oncol.) 64 (1995) 309-315
181. Stewart M.J., Plautz G.E., Del Buono L., Yang Z.Y., Xu L., Gao X., Huang L., Nabel E.G., and Nabel G.J. Gene transfer in vivo with DNA-liposome complexes: Safety and acute toxicity in mice. Hum. Gene Ther. 3 (1992) 267-275
182. Stoppacciaro A., Melani C., Parenza M., Mastracchi A., Bassi C., Baroni C., and Parmiani Colombo M.P. Regression of an established tumor genetically modified to release a granulocyte-colony stimulating factor requires granulocyte T-cell cooperation and T-cell produced interferon γ. J. Exp. Med. 178 (1993) 151-161
183. Stratford-Perricaudet L.D., Levrero M., Chasse J.F., Perricaudet M., and Briand P. Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Hum. Gene Ther. 1 (1990) 241-256
184. Sulé-Suso J., Arienti F., Melani C., Colombo M.P., and Parmiani G. A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes. Eur. J. Immunol. 25 (1995) 2737-2742
185. Sun W.H., Burkholder J.K., Sun J., Culp J., Turner J., Lu X., Pugh T., and Yang N.S. In vivo cytokine gene transfer by gene gun reduces tumor growth in mice. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 2889-2893
186. Tahara H., Zeh H.J., Storkus W.J., Pappo I., Watkins S.C., Gubler U., Wolf S.F., Robbins P.D., and Lotze M.T. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 54 (1994) 182-189
187. Tahara H., Zitvogel L., Storkus W.J., Zeh III H.J., McKinney T.G., Schreiber R.D., Gubler U., Robbins P.D., and Lotze M.T. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J. Immunol. 154 (1995) 6466-6474
188. ten Bosch G.J.A., Toornvliet A.C., Friede T., Melief C.J.M., and Leeksma O.C. Recognition of peptides corresponding to the joining region of p210 bcr-abl protein by human T cells. Leukemia 9 (1995) 1344-1348
189. Tepper R.I., Pattengale P.K., and Leder P. Murine interleukin-4 displays potent antitumor activity in vivo. Cell (Cambridge, Mass.) 57 (1989) 503-512
190. Tepper R.I., Coffman R.L., and Leder P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 257 (1992) 548-551
191. Uchiyama A., Hoon D.S.B., Morisaki T., Kaneda Y., Yuzuki D., and Morton D.L. Transfection of interleukin-2 gene into human melanoma cells augments cellular immune response. Cancer Res. 53 (1993) 949-952
192. Vagliani M., Rodolfo M., Cavalo F., Parenza M., Melani C., Parmiani G., Forni G., and Colombo M.P. Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells. Cancer Res. 56 (1996) 467-470
193. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Knuth A., and Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254 (1991) 1643-1647
194. Van Pel A., van der Fruggen P., Coulie P.G., Brichard V.G., Lethé B., Van den Eynde B., Uyttenhove C., Renauld J.-C., and Boon T. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol. Rev. 145 (1995) 229-250
195. Vieweg J., Boczkowski D., Roberson K.M., Edwards D.W., Philip M., Philip R., Rudoll T., Smith C., Robertson C., and Gilboa E. Efficient gene transfer with adeno-associated virus-based plasmid complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res. 55 (1995) 2366-2372
196. Vile R.G., Nelson J.A., Castleden S., Chong H., and Hart I.R. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 54 (1994) 6228-6234
197. Vink A., Coulie P., Warnier G., Renault J.-C., Stevens M., Donckers D., and Van Snick J. Mouse plasmacytoma growth in vivo: Enhancement by interleukin-6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor. J. Exp. Med. 172 (1990) 997-1000
198. Walsh P., Dorner A., Duke R.C., Su L.-J., and Glode L.M. Macrophage colony-stimulating factor complementary DNA: A candidate for gene therapy in metastatic melanoma. J. Natl. Cancer Inst. 87 (1995) 809-816
199. Wang J.M., Taraboletti G., Matsushima K., Van Damme J., and Mantovani A. Induction of hepatotactic migration of melanoma cells by neutrophil activating protein/IL-8. Biochem. Biophys. Res. Commun. 169 (1990) 165-170
200. Weitzman M.D., Wilson J.M., and Eck S.L. Adenovirus vectors in cancer gene therapy. In: Sobol R.E., and Scanlon K.J. (Eds). The Internet Book of Gene Therapy: Cancer Therapeutics (1995), Appleton & Lange, Stamford, Connecticut. 17-25
201. Wolfel T., Hauer M., Schneider J., Serrano M., Wölfel C., Klehmann-Hieb E., DePlaeu E., Hankein T., Meyer zum Buschenfelde K.-H., and Beach D. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269 (1995) 1281-1284
202. Yagi K., Hayashi Y., Ishida N., Ohbayashi M., Ohishi N., Mizuno M., and Yoshida J. Interferon-beta endogenously produced by intratumoral injection of cationic liposome-encapsulated gene: Cytocidal effect on glioma transplanted into nude mouse brain. Biochem. Mol. Biol. Int. 32 (1994) 167-171
203. Yamashiro S., Takeya M., Nishi T., Kuratsu J., Yoshimura T., Ushio Y., and Takahashi K. Tumor-derived monocyte chemoattractant protein-1 induces intratumoral infiltration of monocyte-derived macrophages subpopulation in transplanted rat tumors. Am. J. Pathol. 145 (1994) 856-867
204. Yannelli J.R., Hyatt C., Johnson S., Hwu P., and Rosenberg S.A. Characterization of human tumor cell lines transduced with the cDNA encoding either tumor necrosis factor a (TNF-α) or interleukin-2 (IL2). J. Immunol. Methods 161 (1993) 77-90
205. Yu S.F., von Ruden T., Kantoff P.W., Garber C., Seinberg M., Ruther U., Anderson W.F., Wagner E., and Gilboa E. Self inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 3194-3198
206. Zatloukal K., Schneeberger A., Berger M., Schmidt W., Koszik F., Kutil R., Cotten M., Wagner E., Buschle M., Maass G., Payer R., Stingl G., and Birnstiel M.L. Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. J. Immunol. 154 (1995) 3406-3419
207. Zitvogel L., Tahara H., Cai Q., Storkus W.J., Muller G., Wolf S.F., Gately M., Robbins P.D., and Lotze M.T. Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Hum. Gene Ther. 5 (1994) 1493-1506